EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.
暂无分享,去创建一个
[1] Derek S. Chan,et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer , 2012, Gut.
[2] M. Barbacid,et al. Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR. , 2012, Bioorganic & medicinal chemistry letters.
[3] A. Siriwardena,et al. EGFR and KRAS Mutational Analysis and Their Correlation to Survival in Pancreatic and Periampullary Cancer , 2012, Pancreas.
[4] M. Kanda,et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. , 2012, Gastroenterology.
[5] Carlos Cuevas,et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.
[6] D. Tuveson,et al. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma , 2012, The Journal of experimental medicine.
[7] D. Tuveson,et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. , 2012, Cancer discovery.
[8] A. Maitra,et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] P. Vogt,et al. PI3K and STAT3: a new alliance. , 2011, Cancer Discovery.
[10] D. Levy,et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. , 2011, Cancer research.
[11] M. Barbacid,et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. , 2011, Cancer cell.
[12] Jason Y. Park,et al. Molecular signatures of pancreatic cancer. , 2011, Archives of pathology & laboratory medicine.
[13] S. Akira,et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. , 2011, Cancer cell.
[14] Shizuo Akira,et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. , 2011, Cancer cell.
[15] Altaf Mohammed,et al. The Epidermal Growth Factor Receptor Inhibitor Gefitinib Prevents the Progression of Pancreatic Lesions to Carcinoma in a Conditional LSL-KrasG12D/+ Transgenic Mouse Model , 2010, Cancer Prevention Research.
[16] Andrew Menzies,et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.
[17] M. Barbacid,et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. , 2010, Cancer cell.
[18] David Allard,et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.
[19] P. Majumder,et al. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. , 2009, Gastroenterology.
[20] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[21] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[22] R. Schmid,et al. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. , 2007, Cancer cell.
[23] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Barbacid,et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. , 2007, Cancer cell.
[25] T. Yeatman,et al. EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma. , 2006, The Journal of surgical research.
[26] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[27] S. Leach,et al. Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates , 2005, Development.
[28] M. Barbacid,et al. Tumour biology: Senescence in premalignant tumours , 2005, Nature.
[29] R. Hruban,et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.
[30] Hidetaka Mochizuki,et al. The Correlation Between Cytoplasmic Overexpression of Epidermal Growth Factor Receptor and Tumor Aggressiveness: Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma , 2004, Pancreas.
[31] R. DePinho,et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. , 2003, Genes & development.
[32] Manuel Serrano,et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. , 2003, Cancer cell.
[33] Ming-Sound Tsao,et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. , 2002, Molecular cancer therapeutics.
[34] Ming-Sound Tsao,et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. , 2002, Molecular cancer therapeutics.
[35] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[36] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] H. Friess,et al. Chronic pancreatitis is associated with increased concentrations of epidermal growth factor receptor, transforming growth factor alpha, and phospholipase C gamma. , 1994, Gut.
[38] National Cancer Institute of Canada Clinical Trials Group. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] P. Pour,et al. Ductal metaplasia of human exocrine pancreas and its association with carcinoma. , 1985, Cancer research.